Dr. Nigel Aminake Makoah is a protein biochemist deeply dedicated to infectious diseases research. He obtained his MSc. in Biochemistry in 2006, establishing the foundation for a career marked by notable achievements. During his doctoral studies at the University of Wuerzburg, he made significant strides by assessing novel pharmacological compounds for dual activity against malaria and HIV while characterizing the malaria parasite's proteasome for potential therapeutic targets. Post-Ph.D., he received the prestigious Georg Forster Postdoctoral Fellowship to develop an antimalarial screening platform. Dr. Makoah furthered his impact at the University of Cape Town, evaluating drug candidates' pharmacokinetic properties and identifying drug targets for tuberculosis. Before joining the University where is currently affiliated, he worked as a senior scientist at the National Institute for Communicable Diseases in Johannesburg, where he developed a passion for designing antigens and antibodies for developing therapeutics. Currently, he is focusing on vital research involving native-like proteins of medically relevant viruses, including SARS-CoV-2, CCHFV, and CHIKV. Dr. Makoah's commitment to advancing diagnostics, prevention, and therapies against infectious pathogens showcases his dedication to public health and scientific progress.